ADx NeuroSciences
State-of-the-art biomarker assays for neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
* | €40.0m Valuation: €40.0m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ADx NeuroSciences, founded in 2011 and based in Ghent, Belgium, specializes in the development of diagnostic biomarkers for neurodegenerative diseases. The company leverages over 45 years of combined expertise in biomarker development and disease research to create state-of-the-art antibodies and immunoassays. ADx NeuroSciences serves clients in the life sciences sector, including pharmaceutical companies and research institutions, by providing tailor-made, high-quality diagnostic solutions. Operating in the highly specialized market of neurodegenerative disease diagnostics, the company generates revenue through the sale of its proprietary biomarkers and immunoassays.
Keywords: diagnostic biomarkers, neurodegenerative diseases, antibodies, immunoassays, life sciences, pharmaceutical, research institutions, high performance, unique solutions, Ghent.